Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) was upgraded by equities research analysts at TheStreet from a “d+” rating to a “c-” rating in a report issued on Friday.

Several other brokerages have also recently commented on VNDA. Zacks Investment Research upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, February 18th. Jefferies Group LLC reiterated a “buy” rating and set a $21.00 price target on shares of Vanda Pharmaceuticals in a research report on Wednesday, April 12th. CIBC reiterated an “outperform” rating and set a $21.00 price target on shares of Vanda Pharmaceuticals in a research report on Wednesday, April 12th. Finally, Oppenheimer Holdings Inc. began coverage on shares of Vanda Pharmaceuticals in a research report on Wednesday, April 12th. They set an “outperform” rating and a $21.00 price target for the company. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $21.13.

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) traded down 4.07% during mid-day trading on Friday, reaching $14.15. 285,025 shares of the company were exchanged. Vanda Pharmaceuticals has a 12 month low of $8.90 and a 12 month high of $18.00. The stock’s market capitalization is $630.41 million. The firm has a 50-day moving average price of $14.31 and a 200 day moving average price of $14.83.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.13) by $0.04. Vanda Pharmaceuticals had a negative return on equity of 16.13% and a negative net margin of 23.07%. The business had revenue of $37.42 million for the quarter, compared to analyst estimates of $38.35 million. Equities research analysts anticipate that Vanda Pharmaceuticals will post ($0.70) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Vanda Pharmaceuticals Inc. (VNDA) Upgraded by TheStreet to C-” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/05/17/vanda-pharmaceuticals-inc-vnda-upgraded-by-thestreet-to-c.html.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Point72 Asset Management L.P. boosted its position in shares of Vanda Pharmaceuticals by 1,544.3% in the first quarter. Point72 Asset Management L.P. now owns 2,484,500 shares of the biopharmaceutical company’s stock worth $34,783,000 after buying an additional 2,333,400 shares in the last quarter. Credit Suisse AG boosted its position in shares of Vanda Pharmaceuticals by 14.6% in the first quarter. Credit Suisse AG now owns 213,808 shares of the biopharmaceutical company’s stock worth $2,993,000 after buying an additional 27,252 shares in the last quarter. Gotham Asset Management LLC boosted its position in shares of Vanda Pharmaceuticals by 178.9% in the first quarter. Gotham Asset Management LLC now owns 167,953 shares of the biopharmaceutical company’s stock worth $2,351,000 after buying an additional 107,736 shares in the last quarter. Nexthera Capital LP purchased a new position in shares of Vanda Pharmaceuticals during the first quarter worth about $7,171,000. Finally, Perceptive Advisors LLC purchased a new position in shares of Vanda Pharmaceuticals during the first quarter worth about $507,000. Hedge funds and other institutional investors own 95.69% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

5 Day Chart for NASDAQ:VNDA

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.